Shares Plunge 21.5% After UnitedHealth Beats Q4 But Flags Cost, Reimbursement Risks
UnitedHealth Group delivered Q4 adjusted EPS above consensus, but shares tumbled 21.5% due to a spike in medical costs and a widened medical care ratio. Management warned that modest Medicare Advantage reimbursement increases for 2027 could further pressure margins.
1. Q4 Earnings Beat Fails to Halt Stock Slide
UnitedHealth Group reported fourth-quarter earnings per share of $5.10, topping consensus estimates by $0.12, and achieved revenue growth of 8% year-over-year to $95.4 billion. Despite the outperformance, the shares fell 21.5% following the release as medical cost ratios climbed to 85.2%, up from 83.7% a year earlier, driven by higher hospitalization rates and specialty drug expenses. Investors reacted to guidance that forecast a narrowing operating margin for full-year 2026, reflecting continued pressure from elevated care utilization and reimbursement uncertainties in its Medicare Advantage business.
2. Dividend Remains Intact Despite Cash Flow Headwinds
After a 41% drop in full-year net income to $13.2 billion—attributable to rising medical costs, a $1.1 billion restructuring charge and a $350 million expense related to a cybersecurity incident—UnitedHealth affirmed its quarterly dividend of $1.75 per share. Free cash flow is projected to decline to $18 billion in 2026 from $22 billion in 2025, yet management cites a cash cushion and disciplined capital allocation plan as sufficient to maintain the current payout ratio of 25% of operating cash flow.
3. Modest Medicare Advantage Rate Increase Offers Limited Relief
The Centers for Medicare & Medicaid Services proposed a 1.3% increase in payment rates to private Medicare Advantage plans for 2027, below the industry’s 3.5% request. As UnitedHealth’s Medicare and Retirement segment accounted for 40% of total 2025 revenue, this restrained uplift could shave approximately $350 million from the segment’s top line next year. The company reiterated its intent to leverage targeted risk-adjustment strategies and expand supplemental benefit offerings to offset rate pressure.
4. Long-Term Growth Strategy Supports Buy-the-Dip Thesis
Management reaffirmed a 13–16% annual growth target over the next five years, underpinned by planned investments in artificial intelligence to reduce administrative costs by an estimated $1.2 billion in 2026. Insider purchases totaled $85 million in the past quarter, signaling confidence at the executive level. Analysts remain divided, but those bullish on a recovery point to UnitedHealth’s diversified services portfolio, accelerating Medicaid enrollment and expanded behavioral health offerings as catalysts for margin expansion beyond 2027.